USPTO serial 79307379
ADRESTIA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 26, 2022
- Examiner
- MURRAY, GEORGE WILLIAM
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ADRESTIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
BEN NATTER
BEN NATTER HAUG PARTNERS, LLP745 Fifth AvenueNew York, NY 10151UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in science; biological preparations for use in science; biochemicals for research use; cell lines and bio-production cell lines for scientific, laboratory or medical research; reagents, plasmids and assays for scientific, genetic and medical research; molecular biology research tools, in the nature of biological and biochemical reagents; biological and chemical reagents for research use; chemical reagents for scientific and research purposes; proteins in raw material form for scientific and medical research; gene extracts for research purposes; chemicals and biochemicals for drug discovery, lead identification, diagnostics, profiling and research | ACTIVE | — |
| 005 | Medical and veterinary preparations for the treatment of immune response disorders, cardiovascular diseases, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and infectious diseases in humans and animals; pharmaceutical substances and preparations for human use for the diagnosis and treatment of immune response disorders, cardiovascular diseases, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and infectious diseases; biopharmaceutical substances and preparations for human use for use in the diagnosis and treatment of immune response disorders, cardiovascular diseases, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and infectious diseases; reagents, diagnostic preparations and therapeutic preparations in the nature of biological, biochemical and chemical reagents and vaccines for medical purposes; biological preparations for medical purposes, for the diagnosis and treatment of immune response disorders, cardiovascular diseases, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and infectious diseases; medical preparations for use in gene therapy; diagnostic preparations for medical purposes; therapeutic and diagnostic preparations, namely, small molecules for medical use | ACTIVE | — |
| 042 | Medical, scientific and industrial research services in the field of cells, cell therapies, genome editing, genetic engineering and gene therapies and targeting therapies to individuals; pharmaceutical and biopharmaceutical research and development services; medical and pharmacological research services; examination and testing of genes for scientific research purposes; development, examination and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, examination and testing of medicaments products; development of test systems for pharmaceutical and biopharmaceutical products; development of databases in the medical, pharmaceutical and biopharmaceutical field; development of gene databases; research and development services in the creation of databases and collections of information on biologicals, genetic material, genetic information, chemicals and compounds for research purposes; providing biological and medical research information; providing scientific research information and data in relation to health and disease state; medical research into personalised medicine; medical research services in the field of personalised diagnostics, medical research services in the field of personal medical profiles; provision of scientific research information in the field of personalised medicine; pharmaceutical drug development services; consultancy and advisory relating to all the aforesaid services | ACTIVE | — |
| 044 | Medical services; medical and pharmaceutical advisory and consultancy services; preparing pharmaceuticals, namely pharmaceutical compounding services for others; providing personalised medicine services and personalised medical diagnostic reporting services; providing personal medical information; provision of medical information; provision of information to enable human diagnosis of medical conditions; providing medical information to enable healthcare professionals to enable the monitoring of patients; providing medical information to healthcare professionals to enable the assessment of progress in disease and treatment; consultancy and advisory relating to all the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Adrestia Therapeutics Ltd
- Other trademarks owned by Adrestia Therapeutics Ltd
- Other trademarks owned by Adrestia Therapeutics Ltd
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ADRESTIA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 26, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 2, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 2, 2022 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 26, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 27, 2022 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Apr 26, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 8, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 8, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 6, 2022 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 20, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 20, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 20, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 19, 2022 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 19, 2022 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 19, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 3, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 23, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 23, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 23, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 23, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 22, 2021 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Dec 22, 2021 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 22, 2021 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 14, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 14, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 14, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 11, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 21, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 21, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jun 12, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 11, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 7, 2021 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| May 29, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 28, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 28, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 30, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 26, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 25, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |